Medivation (MDVN) Given Coverage Optimism Score of 0.22
Media coverage about Medivation (NASDAQ:MDVN) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Medivation earned a news impact score of 0.22 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 47.4451860957354 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Medivation (NASDAQ MDVN) traded up $0.04 during trading hours on Tuesday, reaching $81.48. 8,577 shares of the company traded hands, compared to its average volume of 3,545,656. The company has a market capitalization of $13,520.00, a PE ratio of -69.64 and a beta of 0.60. Medivation has a twelve month low of $26.41 and a twelve month high of $81.48. The company has a current ratio of 4.32, a quick ratio of 4.32 and a debt-to-equity ratio of 0.03.
Medivation Company Profile
Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).
Receive News & Ratings for Medivation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivation and related companies with Analyst Ratings Network's FREE daily email newsletter.